Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naphazoline + mepyramine + dexpanthenol is a fixed-dose combination of three small molecule drugs primarily formulated for intranasal use to treat symptoms of nasal congestion and related upper respiratory tract discomfort. - **Naphazoline** is a sympathomimetic alpha-adrenergic agonist which acts as a vasoconstrictor on mucosal blood vessels, rapidly reducing swelling and congestion. - **Mepyramine** (also known as pyrilamine) is a first-generation antihistamine acting as a histamine H1 receptor antagonist, reducing itching and other allergy symptoms. - **Dexpanthenol** is a provitamin of B5 with moisturizing and epithelial barrier-restoring properties; it protects and promotes regeneration of mucosal surfaces. This combination is used for symptomatic relief in conditions such as the common cold and rhinitis. The combination aims to provide synergistic decongestant, antihistaminic, and mucosal protective effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naphazoline + mepyramine + dexpanthenol.